For molecular biologists, new drug development using oligonucleotides has long been regarded as a dream technology. But with Alnylam Pharmaceuticals Inc.'s recent success in a Phase III clinical study for patisiran, RNA interference companies such as OliX Pharmaceuticals Inc. hope that this no longer remains just a dream. ([A#sc099529])
"If we can develop drugs in this way, we will be able to develop them infinitely in a very short...








